{
  "abstract": "Background Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used for metabolic disease, but their safety profile in patients with chronic pancreatitis (CP) is uncertain.Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX platform. Adults (≥18 years) with CP (ICD-10-CM K86.0/K86.1) were classified by exposure to dulaglutide, semaglutide, or tirzepatide (GLP1a cohort) versus no GLP-1 analogue exposure (non-GLP1a cohort). Before matching, cohort sizes were 10,406 and 235,052; after matching, 10,082 patients were included in each cohort. We conducted risk analyses and Kaplan-Meier time-to-event analyses, excluding patients with each outcome prior to the analysis window.Results After matching, the mean follow-up was 605.022 days (SD 388.068) in the GLP1a cohort and 706.789 days (SD 416.087) in the non-GLP1a cohort; median follow-up was 588 (IQR 831) vs 879 (IQR 807), respectively. Nausea/vomiting occurred in 656/4,938 (risk 0.133) vs 1,099/5,585 (risk 0.197) with HR 0.710 (95% CI 0.645–0.783). Bowel obstruction/ileus occurred in 241/9,103 (risk 0.026) vs 466/8,949 (risk 0.052) with HR 0.556 (0.476–0.649), and upper gastrointestinal bleeding in 355/8,536 (risk 0.042) vs 608/8,657 (risk 0.070) with HR 0.659 (0.578–0.751).Biliary/procedural outcomes were lower, including cholecystectomy (0.023 vs 0.049; HR 0.486, 0.412–0.572) and ERCP (0.026 vs 0.064; HR 0.420, 0.362–0.488). Additional associations included lower insulin initiation (0.178 vs 0.269; HR 0.731, 0.658–0.812), heart failure (0.061 vs 0.101; HR 0.687, 0.613–0.770), acute kidney injury (0.086 vs 0.150; HR 0.643, 0.580–0.712), malnutrition (0.049 vs 0.107; HR 0.491, 0.438–0.550), and myocardial infarction (0.039 vs 0.054; HR 0.818, 0.712–0.939). (IDDF2026-ABS-0333 Figure 1. Time to event hazard ratio of different clinical outcomes on GLP-1 RA).Conclusions In this cohort of CP, exposure to dulaglutide, semaglutide, or tirzepatide was associated with lower risks across multiple outcome domains compared with non-exposed controls.Abstract IDDF2026-ABS-0333 Figure 1",
  "authors": [
    {
      "affiliations": [
        "Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom"
      ],
      "name": "Arkadeep Dhali"
    },
    {
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center, United States"
      ],
      "name": "Fayaz Khan"
    }
  ],
  "title": "IDDF2026-ABS-0333 Real-world gastrointestinal, nutritional, biliary, and metabolic outcomes of GLP-1-based therapy in chronic pancreatitis",
  "uid": "23ecd991-b58e-5748-8f35-b227ac77d9d6"
}